Cosmos Health Inc. - SIC # 5130 -

Ticker Exchange SIC # Website Latest Ticker
COSM Nasdaq 5130 www.cosmosholdingsinc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cosmos Health Inc.

Cosmos Health enters U.S. market with DolCas Biotech agreement - Jun 25th, 2025 9:00 am
Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech - Jun 24th, 2025 8:55 am
RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven - May 15th, 2025 12:30 pm
Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven - May 15th, 2025 7:30 am
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units - May 7th, 2025 12:30 pm
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq - May 6th, 2025 11:40 am
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000 - Apr 30th, 2025 10:50 am
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million - Apr 16th, 2025 10:45 am
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L - Apr 9th, 2025 11:40 am
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order - Apr 8th, 2025 8:45 am
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates - Feb 26th, 2025 9:30 am
Bullish Cosmos Health Insiders Loaded Up On US$539.0k Of Stock - Feb 20th, 2025 3:18 am
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1 - Feb 18th, 2025 6:30 am
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market - Feb 11th, 2025 8:15 am
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market - Feb 10th, 2025 11:30 am
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations - Feb 10th, 2025 7:45 am
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility - Feb 7th, 2025 8:00 am
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar - Feb 6th, 2025 1:50 pm
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market - Feb 5th, 2025 9:05 am
Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow - Jan 28th, 2025 9:00 am